# A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Study · id `cardio:ct-nct07761117` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07761117](<https://clinicaltrials.gov/study/NCT07761117>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07761117

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6950 participants.

## Technical summary

Registry record NCT07761117. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2029-09-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 6950 participants (planned count; ClinicalTrials.gov record NCT07761117, source copy `cardio:ctgov-nct07761117-2026-09-28`, retrieved 2026-10-26)
- Started: 2026-08-24 (actual) (ClinicalTrials.gov record NCT07761117, source copy `cardio:ctgov-nct07761117-2026-09-28`, retrieved 2026-10-26)
- Primary completion: 2029-09-03 (anticipated) (ClinicalTrials.gov record NCT07761117, source copy `cardio:ctgov-nct07761117-2026-09-28`, retrieved 2026-10-26)
- Completion: 2029-09-03 (anticipated) (ClinicalTrials.gov record NCT07761117, source copy `cardio:ctgov-nct07761117-2026-09-28`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Brazil; Bulgaria; Canada; China; Czechia; France; Germany; Greece; Hungary; India; Italy; Japan; Malaysia; Mexico; Netherlands; Poland; Romania; Slovakia; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Arab Emirates; United Kingdom; Vietnam (ClinicalTrials.gov record NCT07761117, source copy `cardio:ctgov-nct07761117-2026-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07761117-2026-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
- Acronym: Elevate-HF
- Condition: Heart Failure With Preserved Ejection Fraction (HFpEF)
- Condition: Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Intervention (Drug): Elecoglipron
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 78cd5621e82f2ff33aa2c9a0eb9cb8d915467094a7492539be48f39b48929f68
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
